[Management of lymphoma with respect to pathologic classification: updates and controversies]

Zhonghua Bing Li Xue Za Zhi. 2009 Nov;38(11):724-7.
[Article in Chinese]
No abstract available

MeSH terms

  • Anaplastic Lymphoma Kinase
  • Antibodies, Monoclonal, Murine-Derived / therapeutic use
  • Antineoplastic Agents / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Bleomycin / therapeutic use
  • Cyclophosphamide / therapeutic use
  • Dacarbazine / therapeutic use
  • Doxorubicin / therapeutic use
  • Hodgkin Disease / drug therapy
  • Humans
  • Lymphoma / classification
  • Lymphoma / drug therapy*
  • Lymphoma / pathology*
  • Lymphoma, Large B-Cell, Diffuse / drug therapy
  • Lymphoma, Large-Cell, Anaplastic / drug therapy
  • Lymphoma, Large-Cell, Anaplastic / metabolism
  • Lymphoma, Non-Hodgkin / drug therapy
  • Prednisone / therapeutic use
  • Receptor Protein-Tyrosine Kinases / metabolism
  • Rituximab
  • Vinblastine / therapeutic use
  • Vincristine / therapeutic use

Substances

  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Agents
  • Bleomycin
  • Rituximab
  • Vincristine
  • Vinblastine
  • Dacarbazine
  • Doxorubicin
  • Cyclophosphamide
  • Anaplastic Lymphoma Kinase
  • Receptor Protein-Tyrosine Kinases
  • Prednisone

Supplementary concepts

  • ABVD protocol
  • CHOP protocol